A Phase 2 interventional study of Esketamine and Sirolimus (RAPAMUNE) in Treatment Resistant Depression (TRD), sponsored by Rodolfo Furlan Damiano. Not yet recruiting at 2 sites in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Rodolfo Furlan Damiano · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Depressive Disorder, Treatment-Resistant with a site in Brazil — 3 open to participants now, 3 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Brazil.
Among the 12 studies in Depressive Disorder, Treatment-Resistant with a site in Brazil, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 12th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →3 of the 12 studies in Depressive Disorder, Treatment-Resistant with a site in Brazil are open now. Recruiting first, the newest first:
Universidade do Sul de Santa Catarina · Sites in Brazil
Ages 18–69
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 1
First in 2013; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 120 across the 11 interventional studies, 1,539 across the 1 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 6 most frequent:
This is the only study on the registry with Rodolfo Furlan Damiano as lead sponsor.
Rodolfo Furlan Damiano has 1 study filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies in Depressive Disorder, Treatment-Resistant with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07696871Universidade do Sul de Santa CatarinaCannabidiol Oil for Treatment-Resistant Major Depression | 2026-12-31 |
| NCT07949500Rodolfo Furlan DamianoEsketamine Plus Sirolimus for Adults With Depression Who Have Not Responded to Esketamine | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Depressive Disorder, Treatment-Resistant with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine whether combining sirolimus (also called rapamycin) with intravenous esketamine may reduce depression symptoms in adults whose depression did not improve sufficiently after a previous course of intravenous esketamine. Researchers will also assess side effects and how long any improvement lasts.
Approximately 40 adults aged 18 to 60 years will participate at two centers in Sao Paulo State, Brazil. All participants will receive the same treatment: eight esketamine infusions over 4 weeks and a dose of oral sirolimus before the first infusion of each week. There is no placebo group.
After providing informed consent, potential participants will undergo interviews, questionnaires, medical assessments, laboratory testing, and review of records from their previous treatment. Eligible participants will complete symptom questionnaires and clinical ratings before and during treatment and at follow-up visits through Week 12. Dissociation and sedation will be assessed before each infusion and at 40 and 120 minutes after the infusion starts. Additional depression ratings will be obtained 24 hours after the first and last infusions. Clinical monitoring and discharge decisions will be managed by the treating hospital team.
The main outcome is the change in clinician-rated depression severity from the assessment before the first study dose to Week 5, which is 7 days after the last esketamine infusion.
ESKRAP is a phase 2a, open-label, single-arm study evaluating the preliminary antidepressant effects, durability, safety, and tolerability of repeated intravenous esketamine combined with oral sirolimus in adults with major depressive disorder and documented nonresponse to an adequate previous intravenous esketamine course. Approximately 40 participants will be enrolled at two centers in Sao Paulo State, Brazil. The study has no random allocation or comparator group. Findings will be interpreted as preliminary estimates from an uncontrolled study.
Screening and eligibility
Written informed consent is obtained before research procedures. Initial assessment records the current depressive episode and previous treatments, including the number of pharmacological trials, medications, doses and treatment durations, psychotherapy modality and duration, electroconvulsive therapy, and previous ketamine or esketamine courses. With the authorization already documented in the informed consent form, the research team may request relevant records from the treating clinician.
The screening instruments are the Mini International Neuropsychiatric Interview (MINI), Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), Montgomery-Asberg Depression Rating Scale (MADRS; 7-day recall), and screening Columbia-Suicide Severity Rating Scale (C-SSRS). The screening C-SSRS covers lifetime and past-month suicidal ideation and intensity, and lifetime and past-3-month suicidal behavior. ASSIST is used only at screening; it does not by itself establish a substance use disorder diagnosis or its severity. The substance-related exclusion concerns severe substance use disorder that is current or occurred within the preceding 6 months, excluding nicotine and caffeine.
Laboratory and medical findings and documentation of previous esketamine nonresponse are reviewed before the final eligibility decision. Historical depression scale names, assessment dates, and pretreatment and post-treatment scores are documented; different scales are not directly compared to establish prior response. Previous nonresponse is independently adjudicated by two clinicians, with a third clinician resolving disagreement. Final eligibility review and enrollment follow completion of the required screening assessments, examinations, and documentation. Before the first study medication is administered, eligibility is reconfirmed using the Week 1 baseline MADRS and current clinical information. The baseline MADRS is not a duplicate of the screening assessment.
Treatment
Participants receive esketamine 0.375 mg/kg intravenously over 40 minutes, twice weekly for 4 weeks, for a total of eight infusions. Sirolimus 6 mg orally is given approximately 2 hours before the first infusion of each week, for a total of four doses. The two infusions within a week are separated by 2 to 4 days. Eligible participants receiving maintenance esketamine have that regimen replaced by the study infusion schedule during the treatment period, according to the eligibility requirements.
Depression and weekly assessments
The MADRS is administered at the beginning of all eight infusion visits. At the first infusion visit, one MADRS assessment serves as the baseline and first predose assessment and is performed before sirolimus. At the first infusion of Weeks 2, 3, and 4, the weekly MADRS is also performed before sirolimus. At the second infusion of each week, MADRS is performed at the beginning of the visit before esketamine. MADRS is not repeated immediately before the infusion after it has been completed at the beginning of that visit. Additional MADRS assessments occur 24 hours after completion of only the first and eighth infusions.
MADRS uses 7-day recall at screening, baseline, and post-treatment follow-up visits; it uses 24-hour recall at infusion visits 2 through 8 and at the two post-infusion 24-hour assessments. The primary comparison remains the 7-day-recall MADRS assessment at baseline versus Week 5.
The Quick Inventory of Depressive Symptomatology-Self-Report, 16-item version (QIDS-SR16), is the prospective self-report depression measure. PHQ-9 is not administered prospectively. A historical PHQ-9 may still be used as an admissible source of documented prior esketamine nonresponse. QIDS-SR16, the Generalized Anxiety Disorder-7 scale (GAD-7), Brazilian Snaith-Hamilton Pleasure Scale (SHAPS-BR), seven-item Beck Hopelessness Scale (BHS-7), and Clinical Global Impression-Severity scale (CGI-S) are assessed at baseline, before the first infusion of Weeks 2, 3, and 4, and at Weeks 5, 6, 8, 10, and 12. Only the seven BHS-7 items are administered. Clinical Global Impression-Improvement (CGI-I) begins at infusion 2 and is assessed at subsequent infusion visits and follow-up visits, always relative to the Week 1 baseline.
Sleep is assessed with the brief Pittsburgh Sleep Quality Index (B-PSQI) at baseline, Week 4, and Weeks 5, 6, 8, 10, and 12. Health-related quality of life is assessed with SF-12 version 1 at baseline and Weeks 4, 5, and 12; physical and mental component scores are calculated separately, and SF-6D utility is derived from the SF-12 responses. Baseline and Week 12 characterization also includes BIS-11, ASRS v1.1, MSI-BPD, DUREL, and SWEMWBS. MINI and ASSIST are not repeated at baseline or follow-up.
Dissociation, sedation, and clinical safety
The Clinician-Administered Dissociative States Scale (CADSS) and Modified Observer's Assessment of Alertness/Sedation (MOAA/S) are assessed three times per infusion: immediately before intravenous esketamine, 40 minutes after infusion start, and 120 minutes after infusion start. These times are referenced to the actual start of the infusion. The observed postdose CADSS peak is the highest recorded postdose score, not necessarily the 40-minute score; the predose value is its reference. MOAA/S uses the 0-5 scale, with 5 indicating full alertness and lower scores indicating deeper sedation.
For dissociation, the session-specific resolution threshold is the higher of 4 or the same-session predose CADSS total. Time to first documented resolution runs from the first postdose score above that threshold to the first subsequent score at or below it. For sedation, time to first documented recovery runs from the first postdose MOAA/S score below 5 to the first subsequent score of 5. These are observed assessment times; recovery between assessments is not assigned an exact unobserved time. Sessions with an observed episode but no documented recovery are censored at the last scored assessment. Additional clinical scale assessments contribute only when their actual scores and times are documented and available.
Follow-up C-SSRS, Beck Scale for Suicide Ideation (BSI), and Altman Self-Rating Mania Scale (ASRM) are assessed at baseline, at the beginning of subsequent infusion visits, and at Weeks 5, 6, 8, 10, and 12. Follow-up C-SSRS questions cover the interval since the last C-SSRS actually completed. Adverse events, concomitant medications, vital signs, and other protocol-specified safety assessments are reviewed throughout the relevant study periods. Infection surveillance includes in-person infectious disease assessments during each treatment week and at Weeks 5 and 6, with follow-up surveillance through Week 12.
The treating hospital team remains responsible for clinical observation, treatment of acute adverse effects, and discharge. Participants remain under clinical observation for at least 2 hours after infusion completion, or longer if clinically indicated. The three scheduled research scale assessments do not replace this observation or the clinical discharge criteria.
Follow-up and outcomes
Post-treatment visits occur at Weeks 5, 6, 8, 10, and 12. The primary outcome is change in MADRS total score from the Week 1 predose baseline to Week 5, 7 days after the final infusion. Secondary assessments address response, partial response, remission, depressive symptom severity, persistence of improvement, relapse among Week 5 responders, anxiety, anhedonia, hopelessness, sleep, quality of life, and safety. Historical treatment information and baseline characterization measures support eligibility and descriptive analyses; collecting them does not make each item a separate efficacy outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previous adequate intravenous esketamine treatment with documented nonresponse, meeting all applicable requirements below:
Eligibility may be established through either of two entry pathways:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive intravenous esketamine 0.375 mg/kg infused over 40 minutes twice weekly for 4 weeks, for a total of eight infusions. Oral sirolimus 6 mg, administered as three 2 mg tablets, is given under direct observation approximately 2 hours before the first esketamine infusion of each week, for a total of four doses. No additional sirolimus dose is given before the second infusion of the week. Participants are followed for 8 weeks after the treatment period.
Drug: Esketamine · Drug: Sirolimus (RAPAMUNE)
Esketamine hydrochloride is administered intravenously at 0.375 mg/kg over 40 minutes, twice weekly for 4 consecutive weeks, for a total of eight infusions. Infusions are separated by 2 to 4 days and are administered at the study center under medical supervision, with clinical monitoring during infusion and observation for at least 2 hours after each infusion ends.
Also known as: S-ketamine, Esketamine hydrochloride
Sirolimus is administered orally at 6 mg, as three 2 mg Rapamune tablets, once weekly for 4 consecutive weeks, for a total of four doses. Each dose is administered under direct observation at the study center approximately 2 hours before the first esketamine infusion of that week. No additional sirolimus dose is administered before the second weekly esketamine infusion.
Also known as: Rapamycin
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 5
Mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline to Week 5, assessed by independent certified raters. The MADRS is a clinician-rated scale comprising 10 items scored from 0 to 6, with a total score ranging from 0 to 60. Higher scores indicate greater depressive symptom severity. Change is calculated as the Week 5 score minus the baseline score; negative values indicate improvement.
Time frame: Baseline (Week 1, before the first study dose) and Week 5 (7 days after the last esketamine infusion)
Percentage of Participants With Depression Response
Percentage of participants with a reduction of at least 50% in Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline, calculated separately at each specified visit. The MADRS contains 10 items and has a total score ranging from 0 to 60; higher scores indicate more severe depressive symptoms. Baseline is the Week 1 predose assessment.
Time frame: Baseline (Week 1, predose) and Weeks 5, 6, 8, 10, and 12
Percentage of Participants With at Least Partial Depression Response
Percentage of participants with a reduction of at least 25% in Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline, calculated separately at each specified visit. This protocol-defined threshold includes participants with reductions of 50% or greater. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms. Baseline is the Week 1 predose assessment.
Time frame: Baseline (Week 1, predose) and Weeks 5, 6, 8, 10, and 12
Percentage of Participants With Depression Remission
Percentage of participants with a Montgomery-Asberg Depression Rating Scale (MADRS) total score of 10 or lower, calculated separately at each specified visit. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms.
Time frame: Weeks 5, 6, 8, 10, and 12
Percentage of Participants With a MADRS Total Score Below 19
Percentage of participants with a Montgomery-Asberg Depression Rating Scale (MADRS) total score below 19, calculated separately at each specified visit. This threshold includes participants meeting the remission criterion. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms.
Time frame: Weeks 5, 6, 8, 10, and 12
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) Total Score
Mean change from baseline in QIDS-SR16 total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The questionnaire contains 16 items covering nine depressive symptom domains. Domain scores are combined to produce a total score ranging from 0 to 27. Higher scores indicate more severe depressive symptoms. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.
Time frame: Baseline (Week 1, predose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
Mean change from baseline in CGI-S score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The CGI-S is a clinician-rated measure of overall illness severity, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.
Time frame: Baseline (Week 1, predose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12
Clinical Global Impression-Improvement (CGI-I) Score
Mean CGI-I score, calculated separately at each specified post-baseline visit. The CGI-I is a clinician-rated assessment of overall improvement or worsening relative to baseline. Scores range from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. Each rating refers to the participant's condition at baseline; no baseline CGI-I score is subtracted.
Time frame: Before infusions 2-8 during Weeks 1-4 and at Weeks 5, 6, 8, 10, and 12, relative to the Week 1 baseline before the first study dose.
Change in MADRS Total Score From Week 5 During Follow-Up
Mean change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from Week 5 to each specified follow-up visit. Change is calculated as the follow-up score minus the Week 5 score. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms. Positive changes indicate worsening relative to Week 5, and negative changes indicate further improvement.
Time frame: Week 5 and follow-up assessments at Weeks 6, 8, 10, and 12
Time to Depression Relapse Among Week 5 Responders
Time from the Week 5 assessment to the first follow-up assessment showing loss of at least 50% of the improvement in MADRS total score achieved from baseline to Week 5, or a MADRS total score of at least 22, whichever occurs first. Week 5 responders are participants with a reduction of at least 50% from baseline. Time to relapse will be analyzed using Kaplan-Meier methods; participants without observed relapse will be censored at their last assessment.
Time frame: Week 5 through Week 12; relapse assessed at Weeks 6, 8, 10, and 12
Change From Baseline in Generalized Anxiety Disorder-7 (GAD-7) Total Score
Mean change from baseline in GAD-7 total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The GAD-7 contains seven self-report items scored from 0 to 3, yielding a total score ranging from 0 to 21. Higher scores indicate greater anxiety severity. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.
Time frame: Baseline (Week 1, predose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12
Change From Baseline in Brazilian Snaith-Hamilton Pleasure Scale (SHAPS-BR) Total Score
Mean change from baseline in SHAPS-BR total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The SHAPS-BR assesses anhedonia using 14 items scored 0 or 1 according to the Brazilian version. Total scores range from 0 to 14; higher scores indicate greater anhedonia. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.
Time frame: Baseline (Week 1, before the first study dose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12.
Change From Baseline in Seven-Item Beck Hopelessness Scale (BHS-7) Total Score
Mean change from baseline in BHS-7 total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The seven-item scale assesses hopelessness using items scored 0 or 1, yielding a total score ranging from 0 to 7. Higher scores indicate greater hopelessness. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.
Time frame: Baseline (Week 1, before the first study dose) and Weeks 2, 3, 4, 5, 6, 8, 10, and 12.
Change From Baseline in Brief Pittsburgh Sleep Quality Index (B-PSQI) Total Score
Mean change from baseline in B-PSQI total score at the specified post-baseline visits, analyzed using a mixed model for repeated measures. The B-PSQI uses six questions to derive five sleep-quality components, producing a total score ranging from 0 to 15. Higher scores indicate poorer sleep quality. Change is calculated as the post-baseline score minus the baseline score; negative values indicate improvement.
Time frame: Baseline (Week 1, predose) and Weeks 4, 5, 6, 8, 10, and 12
Percentage of Week 5 Responders Meeting Depression Response Criteria at Follow-Up
Among participants with a reduction of at least 50% in Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline at Week 5, the percentage who also meet this response criterion at each specified follow-up visit. Percentages are calculated separately for each visit using Week 5 responders as the reference population. MADRS total scores range from 0 to 60; higher scores indicate more severe depressive symptoms.
Time frame: Week 5 response status and follow-up assessments at Weeks 6, 8, 10, and 12; baseline reference at Week 1
Change From Baseline in SF-12 Physical Component Summary Score
Mean change from baseline in the Physical Component Summary (PCS) score of the 12-Item Short Form Health Survey, version 1 (SF-12v1), at each specified post-baseline visit. The questionnaire assesses health-related quality of life over the preceding 4 weeks. Scores are calculated using the original US norm-based algorithm, with a reference population mean of 50 and standard deviation of 10. Possible scores range from approximately 9.95 to 70.13; higher scores indicate better physical health-related quality of life. Change is the post-baseline score minus the baseline score; positive values indicate improvement. Repeated assessments will be analyzed using a mixed model for repeated measures.
Time frame: Baseline (Week 1, predose) and Weeks 4, 5, and 12
Change From Baseline in SF-12 Mental Component Summary Score
Mean change from baseline in the Mental Component Summary (MCS) score of the 12-Item Short Form Health Survey, version 1 (SF-12v1), at each specified post-baseline visit. The questionnaire assesses health-related quality of life over the preceding 4 weeks. Scores are calculated using the original US norm-based algorithm, with a reference population mean of 50 and standard deviation of 10. Possible scores range from approximately 5.89 to 72.28; higher scores indicate better mental health-related quality of life. Change is the post-baseline score minus the baseline score; positive values indicate improvement. Repeated assessments will be analyzed using a mixed model for repeated measures.
Time frame: Baseline (Week 1, predose) and Weeks 4, 5, and 12
Change From Baseline in SF-6D Health Utility Index
Mean change from baseline in the Short Form Six-Dimension (SF-6D) health utility index at each specified post-baseline visit. Scores are derived from individual SF-12v1 item responses using the SF-12-specific algorithm and UK general population preference weights published by Brazier and Roberts (2004). The measure covers physical functioning, role limitations, social functioning, pain, mental health, and vitality. Scores range from 0.345 to 1.000; higher values indicate better health-related quality of life, and 1.000 represents full health. Change is the post-baseline value minus the baseline value; positive values indicate improvement.
Time frame: Baseline (Week 1, predose) and Weeks 4, 5, and 12
Suicidal Ideation and Suicidal Behavior
Suicidality is assessed with the Columbia-Suicide Severity Rating Scale (C-SSRS) and Beck Scale for Suicide Ideation (BSI). C-SSRS results are participant counts by ideation and behavior category. Baseline and later assessments cover the interval since the last completed C-SSRS; lifetime screening findings are distinguished from interval findings. BSI items 1-5 yield a screening subtotal of 0-10. The 19-item total (0-38) is calculated only when all 19 items are applicable and completed. When items 4 and 5 are both zero, items 6-19 are skipped, the full total remains unavailable, and the subtotal is retained; skipped items are not assigned zero. Higher BSI scores indicate greater suicidal ideation severity. Scoring paths and available denominators are reported. C-SSRS categories, BSI subtotal and BSI full total are summarized separately by visit; no combined score is calculated.
Time frame: Before the first study dose at Week 1 baseline, at the start of infusion visits 2-8 during Weeks 1-4, and at Weeks 5, 6, 8, 10, and 12. C-SSRS intervals begin at the last completed C-SSRS assessment.
Altman Self-Rating Mania Scale (ASRM) Total Score
Mean total score on the Altman Self-Rating Mania Scale (ASRM), calculated separately at each specified visit. The ASRM is a self-report measure of manic symptoms comprising five items scored from 0 to 4. Total scores range from 0 to 20; higher scores indicate greater severity of manic symptoms. Baseline and post-baseline scores are summarized by visit.
Time frame: Before the first study dose at Week 1 baseline, at the start of infusion visits 2-8 during Weeks 1-4, and at Weeks 5, 6, 8, 10, and 12.
Number of Participants With Treatment-Emergent Adverse Events
Number of participants with at least one adverse event that begins or worsens after the first study dose. Events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by system organ class, preferred term, severity, seriousness, and relationship to each study drug. Participants with any adverse event and those with serious adverse events will be reported separately. Each participant will be counted once within each reported category.
Time frame: From the first study dose through Week 12
Dissociative Symptoms Assessed With the Clinician-Administered Dissociative States Scale (CADSS)
CADSS total scores, changes from same-session predose scores, highest observed postdose score, percentage with a postdose score above 4, and time to first documented resolution will be reported separately by infusion visit; no composite score is calculated. CADSS has 23 items scored 0-4, totaling 0-92; higher scores indicate greater dissociation. Postdose minus predose changes above zero indicate worsening. The peak excludes predose. Resolution time is minutes from the first postdose score above max(4, predose score) to the first subsequent score at or below that threshold, using actual assessment times. With no observed episode, time is not applicable; unresolved episodes are censored at the last scored assessment. Additional clinical assessments contribute only if actual scores and times are documented. Discharge alone does not establish resolution; recovery between observed assessments is not imputed.
Time frame: Immediately before infusion and 40 and 120 minutes after infusion start, at each of eight infusion visits during Weeks 1-4; additional scored clinical assessments during the visit, if documented.
Sedation Assessed With the Modified Observer's Assessment of Alertness/Sedation (MOAA/S)
MOAA/S scores, lowest observed postdose score, percentage with a postdose score of 3 or lower, time to first documented recovery, and percentage requiring clinical intervention for sedation will be reported separately by infusion visit; no composite is calculated. MOAA/S ranges from 0 (no response to painful stimulation) to 5 (fully alert); lower scores indicate deeper sedation. The postdose minimum excludes predose. Recovery time is minutes from the first postdose score below 5 to the first subsequent score of 5, using actual assessment times. With no observed sedation, time is not applicable; unresolved episodes are censored at the last scored assessment. Additional scores contribute only if documented with actual times; discharge alone is not scored recovery. Predose sedation is described separately. Clinical interventions are documented measures specifically required to manage sedation beyond routine observation.
Time frame: Predose and 40 and 120 minutes after infusion start at each of eight visits in Weeks 1-4; additional scored clinical assessments if documented, and sedation-related interventions through the end of clinical observation.
Number of Participants With Clinically Significant Treatment-Emergent Clinical or Laboratory Abnormalities
Number of participants with at least one new or worsened abnormality after the first study dose judged clinically significant by the investigator, considering protocol safety criteria, local reference ranges and clinical context; the rationale is documented. Out-of-range values alone do not establish clinical significance. Each participant is counted once overall and once in each applicable category: cardiovascular (blood pressure, heart rate, ECG); hematologic (hemoglobin, hematocrit, leukocytes, absolute neutrophils, platelets); hepatic (ALT, AST, total bilirubin); fasting lipids (total, LDL and HDL cholesterol, triglycerides); or physical examination. Categories may overlap and are not summed. Pretreatment laboratory results, including the Week 1 predose blood count, and predose clinical findings provide baseline references. Baseline abnormalities count only if they worsen after dosing. Serology results used solely for screening eligibility are excluded.
Time frame: First dose through Week 12: vitals at infusions and Weeks 5,6,8,10,12; ECG Weeks 4,5,12; examination Weeks 4,12; CBC before weekly sirolimus in Weeks 1-4; ALT, AST, bilirubin and fasting lipids Week 5; other labs as clinically indicated.
Number of Participants With Treatment-Emergent Infections
Number of participants with at least one new or worsened infection after the first study dose, identified through directed clinical surveillance and investigator assessment. Surveillance includes in-person assessments by an infectious disease physician during Weeks 1-4 and at Weeks 5 and 6, with continued infection surveillance at Weeks 8, 10, and 12. Infections will be recorded regardless of their assessed relationship to either study drug and summarized by infection type, severity, seriousness, and causality. Each participant will be counted once in the overall infection count.
Time frame: From the first study dose through Week 12
Plan to share: Yes — De-identified individual participant data underlying published study results, together with a data dictionary, the study protocol, and the statistical analysis plan, will be made available to qualified researchers upon reasonable request to the principal investigators. Access will be subject to a data use agreement, applicable Brazilian data protection requirements (LGPD), participant consent provisions, sponsor-investigator data rights, and the applicable clinical study and confidentiality agreements.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Individual participant data and supporting documents will be available immediately after publication of the main study results and for 5 years thereafter.
Access criteria: Qualified researchers may request de-identified individual participant data underlying published study results, the data dictionary, study protocol, and statistical analysis plan directly from the principal investigators. Requests may concern secondary analyses related to the study objectives and consistent with participant consent. Access will be subject to a data use agreement, applicable Brazilian data protection requirements (LGPD), sponsor-investigator data rights, and the applicable clinical study and confidentiality agreements.
Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →